Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.47 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.46 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3160275 | 1.00 | HPGD (0.65) | HPGDEPHX1RECQLMBTD1L3MBTL3 | |
| SCHEMBL17128329 | 0.98 | HPGD (0.62) | HPGDEPHX1RECQLMBTD1L3MBTL3 | |
| SCHEMBL24183612 | 0.95 | HPGD (0.64) | HPGDEPHX1RECQLMBTD1L3MBTL3 | |
| SCHEMBL994288 | 0.95 | HPGD (0.58) | HPGDEPHX1RECQLL3MBTL3USP2 | |
| SCHEMBL4624867 | 0.93 | HPGD (0.57) | HPGDEPHX1RECQLMBTD1L3MBTL3 | |
| SCHEMBL1094778 | 0.90 | HPGD (0.57) | HPGDEPHX1RECQLMBTD1L3MBTL3 | |
| SCHEMBL1094777 | 0.90 | HPGD (0.57) | HPGDEPHX1RECQLMBTD1L3MBTL3 | |
| SCHEMBL31209013 | 0.90 | HPGD (0.57) | HPGDEPHX1RECQLMBTD1L3MBTL3 | |
| SCHEMBL13085760 | 0.89 | HPGD (0.55) | HPGDEPHX1RECQLL3MBTL3L3MBTL1 | |
| SCHEMBL4264465 | 0.89 | HPGD (0.55) | HPGDEPHX1RECQLL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714446-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-03-25 | — | — | EP | disclosed |
| CN-119923391-A | Targeted protein degradation of PARP14 for use in therapy | 艾伯维新加坡运营私人有限公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4413985-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2024-08-14 | — | — | EP | disclosed |
| CN-117964623-A | Targeted protein degradation compound and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-115244053-B | Targeted protein degradation compound and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20240024499-A1 | GPC3 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | ARDEAGEN CORP (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240024499-A1 | GPC3 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | ARDEAGEN CORP (US) | 2024-01-25 | — | — | US | disclosed |
| CN-117425646-A | Phosphono derivative, composition thereof and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-01-19 | — | — | CN | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-116897150-A | Novel bifunctional molecules for protein-targeted degradation | 安菲斯塔治疗有限公司 | 2023-10-17 | — | — | CN | disclosed |
| EP-1663975-A1 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060100427-A1 | Novel Gamma Secretase inhibitors | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2006-05-11 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| WO-2005028440-A1 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-20040048848-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | HPGD 3814/4885EPHX1 844/4885RECQL 2162/4885 |
| US-20040048848-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, PSEN1 | HPGD 3246/4885EPHX1 582/4885RECQL 2001/4885 |
| US-20060100427-A1 | Novel Gamma Secretase inhibitors | BACE1, BACE2, PSEN1 | HPGD 2996/4885EPHX1 452/4885RECQL 1849/4885 |
| US-20240024499-A1 | GPC3 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | LGALS3BP, LGALS3, B3GAT3 | HPGD 4015/4885EPHX1 2930/4885RECQL 4807/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | HPGD 3587/4885EPHX1 477/4885RECQL 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.